This article is intended for primary care clinicians, obstetrician-gynecologists, infectious disease specialists, nurses, and other clinicians who care for patients at risk for genital herpes.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This Enduring Material activity, Medscape Education Clinical Briefs, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 9/1/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 0.25 AAFP Prescribed credits.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
AAFP Accreditation Questions
Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 2/2/2017
Valid for credit through: 2/2/2018, 11:59 PM EST
processing....
Genital herpes is a very common and occasionally highly dangerous condition. The authors of the current guidelines, along with an editorial by Hook, provide a review of the epidemiology of genital herpes. The overall prevalence of infection with herpes simplex virus type 2 (HSV-2), the main viral subtype associated with most cases of genital herpes, is 15.3% among US adolescents and adults between 14 and 49 years old. HSV-2 infection is approximately 3 times more common among black individuals compared with whites, and women are twice as likely to harbor infection compared with men. Complicating the epidemiology of genital herpes is that 10% to 20% of new infections are caused by HSV type 1 (HSV-1) only.
The first outbreak of genital herpes is generally the worst, with associated fever and malaise. After a first outbreak, 70% to 90% of patients will have at least 1 more outbreak within 1 year. Asymptomatic patients infected with HSV-2 also have a substantial risk for subsequent symptoms, and 85% of these persons will experience a symptomatic outbreak within 6 months of a positive HSV test result.
Therefore, there is no doubt that genital herpes is common. What other factors are important in forming broad recommendations on screening for HSV and genital herpes, and what did the USPSTF finally recommend in this regard? The answers are detailed in "Recommendation Highlights."
Updated recommendations on genital HSV infection screening advise against routine screening in asymptomatic adolescents and adults, including pregnant women. The USPSTF released the final recommendations and an evidence statement on the use of blood tests for screening online December 20, 2016, in JAMA.[1] They are also available on the USPSTF website.[2]
The final recommendations are consistent with a draft version made available for public comment in August 2016,[3] and update the 2005 recommendations.
After thoroughly reviewing the evidence, the USPSTF concluded that the harms associated with screening outweigh the benefits. These recommendations align with those of other major health organizations, including the American Academy of Family Physicians, American College of Obstetricians and Gynecologists (ACOG), and Centers for Disease Control and Prevention (CDC).
"Despite genital herpes being common, testing is not generally helpful for people without symptoms, in part because early identification does not improve a person's health as there is no cure for herpes," said task force member Ann E. Kurth, PhD, MPH, in a USPSTF news release.
"In addition, because current screening methods are often inaccurate, harms of screening include high false-positive rates and potential anxiety and disruption of personal relationships related to diagnosis," she added.
HSV is a sexually transmitted infection (STI) that affects 1 in 6 US individuals 14 to 49 years old. Although antiviral medications can treat the symptoms of HSV infection and prevent outbreaks, they cannot cure the underlying infection. Two types of HSV exist: HSV-1 (mainly oral infection) and HSV-2 (mainly genital infection).
The recommendations also point out that current tests for HSV-1, which is increasingly becoming a genital infection, cannot identify whether the site of infection is oral or genital.
The task force also recommends intensive behavioral counseling for the prevention of STIs in high-risk individuals and advises close observation of recently infected pregnant women. Although neonatal HSV infection is rare, it can be life threatening, and women with active infection at delivery should be offered the option of cesarean delivery.
In a linked editorial,[4] Edward W. Hook III, MD, from the University of Alabama at Birmingham, supports the recommendations, but with caveats.
"The recommendation against serologic screening for genital HSV is warranted but should concern clinicians and patients and serve as a call to action for the National Institutes of Health, other federal agencies, and industry partners to address this ongoing epidemic, prioritizing development of improved tests and test strategies for diagnosis of HSV," he writes.
He emphasizes genital herpes as a public health problem that is "largely underrecognized." Moreover, HSV infection disproportionately affects non-Hispanic blacks and provides an example of "striking health disparities" in the United States. The strong link between genital herpes and HIV infection provides another reason to tackle the problem.
However, the lack of a national control program, lack of vaccine for prevention, and widespread unawareness of carrier status among infected individuals prove challenging to control efforts. Tests for HSV have not advanced during the last decade, and need improvement. Reducing the stigma and misperceptions about HSV infection is also important to control efforts, according to Dr Hook.
"While it is disappointing that so little progress in test performance has occurred in the more than a decade since the 2005 USPTF recommendation against general population screening for this important and widespread STI, the current USPSTF recommendation should serve to renew efforts to develop better tests for HSV, to improve management strategy, and to address the pervasive and harmful stigma associated with genital herpes," he concludes.
Members of the USPSTF were reimbursed for travel and received an honorarium from the USPSTF, which is an independent voluntary body supported by the Agency for Healthcare Research and Quality. Dr Hook has received grants and/or personal fees from Hologic, Roche Molecular, and Becton Dickinson and research supplies from Cepheid.
JAMA. 2016;316:2493-2494, 2525-2530.